Proprietary R&D

In-house R&D on development of novel platform technologies and drug discovery

Advanced gene cloning tools

Conventional DNA engineering tools often present a major bottleneck for the highly complex demands of modern “synthetic biology” and metabolic engineering approaches.

ACIES BIO has developed a rapid one-step cloning and gene manipulation tools platform by combining large accommodation capacity of artificial chromosome vectors (YAC), TAR-assisted cloning and recombineering techniques, for rapid manipulation of large gene clusters in S. cerevisiae and their efficient transfer to the industrial heterologous hosts. We achieved this by constructing specific bifunctional “Large Pathway Cloning Vectors” (LPCVs), which enable selective in vivo cloning of desired large DNA fragments of interest in yeast. In the next step, LPCV is isolated from yeast and transformed to E. coli, and finally delivered into final heterologous host as prominent secondary metabolite producer (e.g. a high-producing Actinomyces strain).

These in-house developed LPCV vectors allow us to:

  • clone and heterologously express very large DNA segments (over 100kb)
  • “genome-mining” for new complex biosynthetic pathways and secondary metabolites
  • quickly transfer entire biosynthetic pathway encoding known (commercial) metabolite from a wild-type or a poor-growing strain into a high-producing industrial strain

When necessary for efficient expression, state-of-the-art synthetic biology approaches are also being used by ACIES BIO, including re-factoring or de-novo synthesis of the entire biosynthetic gene clusters.
ACIES BIO advanced gene tools platform allows our clients to quickly obtain the target biosynthetic gene cluster of interest for efficient manipulation and/or heterologous expression for production of highly valuable bioactive metabolites from difficult-to cultivate organisms.

Based on the above mentioned success stories, ACIES BIO has set up a novel ABCloneTM cloning service, which enables you to have the desired DNA fragment quickly cloned into a plasmid of your choice, avoiding time-consuming and cost-intensive research. For more information, click here.




Acies was part of Bio World 2017, a unique forum for industry global leaders, policy makers and investors.  
The action is co-financed by the Republic of Slovenia and European Union from European Regional Development Fund.

More >>
Within public call "Enhancing innovation potential and competences in companies", Acies Bio was recognised as one of the innovative companies with best potential to contribute to international competitiveness of Slovenia through smart specialisation.


More >>